Develops peptide drugs for idiopathic pulmonary fibrosis.
Jun 2026Revenue $0.00/yrExpenses $49.5M/yr
No trendCash runway ≈ 2.3 years from Jun 2026
Figures by year
When will Rein Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.00 and expenses $49.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $50.6M | −$50.6M |
| Dec 2024 | $0.00 | $65.1M | −$65.1M |
| Dec 2023 | $0.00 | $16.3M | −$16.3M |
| Dec 2022 | $0.00 | $27.6M | −$27.6M |
| Dec 2021 | $0.00 | $26.6M | −$26.6M |
| Dec 2020 | $0.00 | $20.5M | −$20.5M |
| Dec 2019 | $0.00 | $30.0M | −$30.0M |
| Dec 2018 | $0.00 | $31.9M | −$31.9M |
| Dec 2017 | $0.00 | $23.0M | −$23.0M |
| Dec 2016 | $0.00 | $18.2M | −$18.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.